 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Research > CuraGen Corporation
 |
CuraGen Corporation |
 |
 |
 |
NEWS FROM THE STANDARD |
 |
Gene Schemes
Jul 16 2001 12:00 AM PDT
Biotech: Desperate No More
Jun 27 2001 07:21 AM PDT
Celera Catches the Drug Bug
Jun 13 2001 04:27 PM PDT
DNA Detectives
May 22 2000 12:00 AM PDT
PROFILE |
 |
CuraGen is looking for a few good genes. The company sells data on gene behavior as well as the systems that allow such data to be used. Licensed to drugmakers and agricultural companies, its Web-based GeneScape system gives customers access to its four main databases: GeneCalling, SeqCalling, PathCalling, and SNPCalling. Subsidiary 454 develops pharmacogenetics technologies to improve drug efficacy. CuraGen also has a drug discovery program focused on cancer, autoimmune and inflammatory diseases, and metabolic and central nervous system disorders. Collaborators include Bayer (which owns about 7% of CuraGen), Hoffman-La Roche, and GlaxoSmithKline. Chairman and CEO Jonathan Rothberg owns about 15% of the firm.
COMPETITION |
 |
Affymetrix, Inc. (AFFX)
Incyte Genomics, Inc. (INCY)
Millennium Pharmaceuticals, Inc. (MLNM)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 20.80
1-Yr. Sales Growth: 37.7%
Employees: 358
Revenue per employee: $58,100.56
KEY PEOPLE |
 |
Jonathan M. Rothberg
CEO
David M. Wurzer
CFO
CONTACT INFO |
 |
555 Long Wharf Dr., 11th Fl.
New Haven, CT 06511
US
Phone: 203-401-3330
Fax: 203-401-3333
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |